Shares of Enovis Corporation (NYSE:ENOV – Get Free Report) traded up 7.3% during mid-day trading on Thursday . The stock traded as high as $21.16 and last traded at $21.5060. 111,748 shares were traded during mid-day trading, a decline of 90% from the average session volume of 1,073,055 shares. The stock had previously closed at $20.04.
Analyst Upgrades and Downgrades
A number of equities analysts recently commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Enovis in a research note on Friday, April 10th. Zacks Research cut Enovis from a “hold” rating to a “strong sell” rating in a report on Tuesday. William Blair assumed coverage on Enovis in a research report on Friday, April 17th. They set an “outperform” rating for the company. Wells Fargo & Company cut their target price on shares of Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Finally, Evercore reaffirmed an “outperform” rating and set a $36.00 price target on shares of Enovis in a research note on Friday, May 8th. Seven research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $44.50.
View Our Latest Research Report on Enovis
Enovis Stock Performance
Enovis (NYSE:ENOV – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.82 by $0.07. The business had revenue of $589.15 million during the quarter, compared to analyst estimates of $572.02 million. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The company’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period last year, the company earned $0.81 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities research analysts expect that Enovis Corporation will post 3.12 earnings per share for the current fiscal year.
Insider Transactions at Enovis
In related news, insider Oliver Engert purchased 1,200 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was bought at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the completion of the transaction, the insider directly owned 51,840 shares in the company, valued at $1,120,780.80. This represents a 2.37% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders acquired 4,200 shares of company stock valued at $92,084 in the last ninety days. 2.90% of the stock is owned by company insiders.
Institutional Investors Weigh In On Enovis
Hedge funds and other institutional investors have recently made changes to their positions in the company. Rubric Capital Management LP bought a new stake in shares of Enovis in the 3rd quarter worth about $83,435,000. Paradigm Capital Management Inc. NY raised its position in Enovis by 70.2% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock worth $40,420,000 after purchasing an additional 732,917 shares during the period. AQR Capital Management LLC raised its position in Enovis by 682.6% in the 2nd quarter. AQR Capital Management LLC now owns 498,317 shares of the company’s stock worth $15,627,000 after purchasing an additional 434,646 shares during the period. Front Street Capital Management Inc. raised its position in Enovis by 106.1% in the 1st quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company’s stock worth $16,973,000 after purchasing an additional 384,124 shares during the period. Finally, Quantinno Capital Management LP lifted its stake in Enovis by 130.8% in the first quarter. Quantinno Capital Management LP now owns 604,500 shares of the company’s stock worth $13,752,000 after purchasing an additional 342,556 shares during the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.
Enovis Company Profile
Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.
The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.
Featured Stories
- Five stocks we like better than Enovis
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.
